Source:
Hindustan
Subject: Indian Polity and Governance: Health Regulation, Drug Quality Control, Centre-State Coordination|Target exams: HPPSC HAS, HPRCA
Key points for Prelims: CDSCO, Drugs and Cosmetics Act, 1940, Drugs and Cosmetics Rules, 1945, Himachal Pradesh Drug Control Administration, State Drug Controller, Spurious and substandard drugs
Mains syllabus mapping
- General Studies Paper 2: Health sector regulation, functions of statutory bodies, Centre-State coordination in health governance
- General Studies Paper 2: Government policies and interventions for public health and consumer protection
- General Studies Paper 3: Pharmaceutical industry regulation and quality control
Drugs and Cosmetics Act, 1940: quick facts
- Main objective
- Ensure drugs and cosmetics are safe, effective and of standard quality
- Key sections
- Section 16 (quality standards), Section 17 (misbranding), Section 27 (fake and adulterated drugs)
- Ayurveda and Unani drugs
- Brought within the Act by the 1964 amendment
Key facts for one-day exams
- Himachal Pradesh-manufactured medicines accounted for 2,216 failed samples in the stated period.
- Three drug companies had their licences completely cancelled.
- Forty-seven companies recorded ten or more sample failures each.
- The state department and CDSCO jointly inspected 43 companies.
- The Drugs and Cosmetics Act was enacted in 1940.
Himachal drug quality failure: why in the news?
The Himachal Pradesh government disclosed in the state assembly that 2,216 drug samples failed quality tests over three years and three company licences were cancelled, highlighting the scale of substandard drug manufacturing and regulatory action.
Himachal Pradesh Health and Family Welfare Minister Colonel Dhani Ram Shandil told the state assembly that 2,216 samples of medicines manufactured in the state failed quality tests over the past three years. The figure covers the period from 2024-25 to 1 November 2026, and the tests were conducted in different states and union territories. Three companies lost their licences completely after repeated failures.
According to the minister's written reply to a question by MLA Dr Janak Raj, authorities suspended 1,608 product licences and cancelled 59, taking action against 1,667 product licences in total. Warnings were issued to companies in four cases. The government said directions were issued to recall all substandard medicines from the market, and legal proceedings were initiated in 17 cases.
Forty-seven companies had samples fail at least ten times each. The state drug control department and the Central Drugs Standard Control Organisation jointly inspected 43 of these companies; the state drug controller also inspected them separately. Among the 43, three company licences were cancelled and 19 companies faced full or partial manufacturing stoppages. The restrictions will remain until the companies comply with the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. Drug inspectors have been directed to inspect every manufacturing unit at least once a year.
Key features and how it works
- Section 18 bars the manufacture for sale or distribution, sale, stocking or distribution of drugs or cosmetics that are not of standard quality, or are misbranded, adulterated or spurious.indiankanoon.org
- Section 16 defines the standards of quality for drugs. Section 17 defines misbranding, meaning a drug claiming more therapeutic value than it has. Under Section 18 the manufacturer of such a drug may be asked to suspend it.
- Section 22 sets out the powers of drug inspectors and Section 23 sets the procedure they must follow during raids.
- The Act defines a cosmetic as any product meant to be applied to the human body for beautifying or cleansing. Soaps are excluded from this definition.
- Under the Act, CDSCO approves drugs, oversees clinical trials, lays down drug standards, controls the quality of imported drugs and coordinates State Drug Control Organisations to bring uniform enforcement.cdsco.gov.in
- The Act's rules, the Drugs and Cosmetics Rules, 1945, classify drugs into schedules and lay down rules for storage, sale, display and prescription for each schedule.
Related Static GK and comparison
- Central Drugs Standard Control Organisation (CDSCO): its responsibilities include approval of drugs, clinical trials and laying down drug standards.cdsco.gov.in
- Drugs Controller General of India (DCGI): head of CDSCO, responsible for approval of licences for blood and blood products, IV fluids, vaccines and sera, and for setting manufacturing, sale, import and distribution standards for drugs.
- Indian Pharmacopoeia Commission (IPC): autonomous institution of the Ministry of Health and Family Welfare, formed according to the Drugs and Cosmetics Act of 1940 and established by executive orders in 1956, which sets standards for drugs published as the Indian Pharmacopoeia.
- Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954: a related law on advertising of drugs; listed as a related law in the Wikipedia article on the Drugs and Cosmetics Act.
Drugs and Cosmetics Act, 1940 vs Food Safety and Standards Act, 2006
| Basis | Drugs and Cosmetics Act, 1940 | Food Safety and Standards Act, 2006 (FSSAI) |
|---|---|---|
| Subject regulated | Drugs and cosmetics | Food articles |
| Main regulator | CDSCO and DCGI at the Centre, State Drug Control Organisations | FSSAI, a statutory body under the Ministry of Health and Family Welfare, with State Food Safety Officers |
| Year of law | 1940 | 2006 (FSSAI established 5 September 2008) |
| Legal basis of standards | Quality standards under Section 16; no drug may be sold unless of standard quality (Section 18) | Food safety standards framed by FSSAI through regulations |
| Licensing | Manufacture and sale only under a licence issued under the Act | Licence or registration required for any food business |
Achievements
- The Act has been amended several times, with amendments in 1960, 1962, 1964, 1972, 1982, 1986, 1995 and 2008.
- The Act gives a single national framework that makes the state drug control bodies and CDSCO work under uniform rules, as the Himachal case shows in action: 1,667 product licences were acted on in three years and recall orders were issued.
- The 1964 amendment brought Ayurveda and Unani drugs within the Act's regulatory scope.
Challenges
- The Act lacks specific penalties for violating clinical trial norms. In 2015 the government told the Supreme Court that it could only halt the trials and issue warnings in the HPV vaccination trial case.
- CDSCO has been criticised for lower drug approval standards than the US FDA and European Medicines Agency, and a 2025 investigation criticised lax laws, regulatory loopholes and weak enforcement.
- Repeated failures by the same companies, shown by 47 companies with 10 or more failed samples in Himachal, suggest that licence action alone may not stop repeat violations.
Way forward
- Specific penalties for clinical trial violations should be added to the Act so that the regulator is not limited to halting trials and issuing warnings.
- Joint inspection by central and state bodies, as used for the 43 Himachal companies, should be made routine and linked to outcome monitoring of recalls and licence actions.
- Inspection of every manufacturing unit at least once a year, as directed by the Himachal government under the Act, should be enforced across states with reporting of results.
Connected to this news
Drugs and Cosmetics Act, 1940
The Drugs and Cosmetics Act, 1940 is India's main law regulating the import, manufacture, distribution and sale of drugs and cosmetics, for the safety of patients and consumers.
Timeline
20 November 2026This story
Himachal Pradesh told its assembly that 2,216 drug samples failed quality tests over three years, with 1,667 product licences acted against and three company licences cancelled.
2008
Drugs and Cosmetics (Amendment) Act, 2008.
1995
Drugs and Cosmetics (Amendment) Act, 1995.
1986
Drugs and Cosmetics (Amendment) Act, 1986.
1982
Drugs and Cosmetics (Amendment) Act, 1982.
1972
Drugs and Cosmetics (Amendment) Act, 1972.
Himachal Pradesh connection
Key terms
- Drug quality testing:
- Drug quality testing checks whether a medicine sample meets applicable prescribed standards.
- Drug recall:
- A drug recall is the removal or withdrawal of a medicine from the market.
- Central Drugs Standard Control Organisation:
- The Central Drugs Standard Control Organisation is India's central drug regulatory organisation.
- Licence suspension and cancellation:
- Suspension temporarily interrupts a licence, whereas cancellation terminates it.
Himachal drug quality failure: why it matters for exams
Exams: HPPSC HAS, HPRCA
Syllabus: Governance: Public health regulation; Society: Health and public services
Common mistake: Examiners may present 1,667 as the number of failed samples: it is the number of product licences acted upon; 2,216 samples failed.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Despite a statutory framework under the Drugs and Cosmetics Act, 1940, the recurrence of substandard drug manufacturing reflects weaknesses in regulatory enforcement. Critically examine the challenges in ensuring drug quality in India and suggest measures to strengthen the regulatory system.
Answer outline
- Introduction: Open by noting that Himachal Pradesh's disclosure of 2,216 failed samples over three years shows that a legal framework alone does not guarantee drug quality.
- Body:
- Describe the regulatory architecture: the Drugs and Cosmetics Act, 1940 and Rules, 1945, the roles of CDSCO and state drug control administrations, and joint inspections.
- Examine enforcement challenges: repeat offenders (47 companies failing 10 or more times), gaps between central and state inspection capacity, and the need for annual inspection of every unit with limited inspectors.
- Discuss the effect of enforcement: suspensions, cancellations, recalls and legal cases show action but also how late it comes after substandard medicines reach the market.
- Suggest reforms: strengthen inspector cadre and laboratory capacity, risk-based inspection, digital tracking of batches, stricter penalties for repeat offenders, and better Centre-State coordination.
- Conclusion: Conclude that a credible drug quality regime needs proactive, risk-based regulation backed by adequate state capacity and cooperative federalism, not only punitive action after failure.
Question 2(GS-2 | 150 words | 10 marks)
Discuss how cooperative federalism between the Centre and States can be made more effective in regulating public health sectors such as pharmaceuticals, using the joint inspection model as an illustration.
Answer outline
- Introduction: Note that drug regulation is a shared responsibility where the Centre sets standards and CDSCO coordinates while States enforce licensing and inspection.
- Body:
- Explain the division of roles: CDSCO and state drug controllers conducting joint and separate inspections of the same companies.
- Highlight benefits of the model: pooled expertise, wider coverage, and a single standard under the Drugs and Cosmetics Rules.
- Identify gaps: uneven state capacity, delays in information sharing, and differing enforcement intensity across States.
- Conclusion: Suggest a standardised national database and joint capacity-building as a balanced way forward for cooperative federalism in health regulation.
Stuck? Get it in one tap
Drug quality testing checks whether medicines meet prescribed standards. Samples of medicines made in Himachal Pradesh failed these tests, so authorities ordered recalls and acted against licences. Some factories must stop production fully or partly until they comply with drug laws.
- Governance: Public health regulation
- Society: Health and public services
Related concepts: Drug quality testing, Drug recall, Central Drugs Standard Control Organisation, Licence suspension and cancellation
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which central organisation joined the Himachal Pradesh drug control department in inspecting companies with repeated drug sample failures?
Explanation: The Central Drugs Standard Control Organisation conducted joint inspections with the state department.
- Q2Hard
Consider the following statements about drug quality enforcement in Himachal Pradesh:
- 1. A total of 59 product licences were suspended.
- 2. Forty-three companies were jointly inspected by the state department and CDSCO.
- 3. Drug inspectors were directed to inspect each manufacturing unit at least once a year.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect: 59 product licences were cancelled, while 1,608 were suspended. Statements 2 and 3 are correct: 43 companies underwent joint inspection and annual inspection of each unit was directed.
- Q3Medium
How many samples of Himachal Pradesh-manufactured medicines failed quality tests during 2024-25 to 1 November 2026?
Explanation: A total of 2,216 samples failed quality tests. The figures 1,608 and 1,667 refer to suspended product licences and total product licence actions, respectively; 2,116 is not the recorded sample total.
- Q4Medium
What is the purpose of recalling medicines associated with failed quality samples in Himachal Pradesh?
Explanation: Recall directions seek to withdraw the affected medicines from the market. Inspections and licensing actions are separate regulatory measures and are not replaced by a recall.
Frequently asked questions
1. How many drug samples manufactured in Himachal Pradesh failed quality tests?
A total of 2,216 samples failed during the period covering 2024-25 to 1 November 2026.
2. How many drug company licences were cancelled in Himachal Pradesh?
Three company licences were completely cancelled following repeated sample failures.
3. How many Himachal Pradesh drug product licences were suspended or cancelled?
Authorities suspended 1,608 product licences and cancelled 59, making 1,667 product licence actions.
4. How often must drug manufacturing units in Himachal Pradesh be inspected?
Drug inspectors have been directed to inspect every manufacturing unit at least once a year.
All sources
Original20 November 2026 · Read story

